Individual investors among major shareholders of Keymed Biosciences Inc. (HKG:2162) saw the value of their holdings increase after shares jumped 4.2% last week

To get an idea of ​​who really controls Keymed Biosciences Inc. (HKG:2162), it is important to understand the ownership structure of the company. With a 49% stake, individual investors hold the most shares in the company. In other words, the group is likely to gain the most (or lose the most) from its investment in the business.

Clearly, individual investors benefited the most after the company’s market capitalization rose by HK$434 million last week.

In the table below, we zoom in on the different ownership groups of Keymed Biosciences.

Before looking at the breakdown of owners, note that our analysis indicates that 2162 is potentially overvalued!

SEHK: 2162 Ownership Breakdown September 16, 2022

What does institutional ownership tell us about Keymed Biosciences?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We see that Keymed Biosciences has institutional investors; and they own a good part of the shares of the company. This suggests some credibility with professional investors. But we cannot rely solely on this fact since institutions sometimes make bad investments, like everyone else. If multiple institutions change their minds on a stock at the same time, you could see the stock price drop quickly. So it’s worth checking out the Keymed Biosciences earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
SEHK: 2162 Earnings and Revenue Growth September 16, 2022

Hedge funds do not have many shares in Keymed Biosciences. Looking at our data, we can see that the largest shareholder is Moonshot Holdings Limited with 28% of the shares outstanding. Meanwhile, the second and third largest shareholders hold 9.3% and 5.8% of the outstanding shares respectively.

Upon closer inspection, we found that more than half of the company’s shares are held by the top 6 shareholders, suggesting that the interests of the larger shareholders are to some extent balanced by those of the smaller ones.

While it makes sense to study data on a company’s institutional ownership, it also makes sense to study analyst sentiment to find out which way the wind is blowing. A number of analysts cover the stock, so you can look at growth forecasts quite easily.

Insider ownership of Keymed Biosciences

The definition of an insider may differ slightly from country to country, but board members still matter. The management of the company runs the company, but the CEO will answer to the board of directors, even if he is a member of it.

Most view insider ownership as a positive because it can indicate that the board is well aligned with other shareholders. However, there are times when too much power is concentrated within this group.

Our data does not allow us to confirm that the members of the board of directors personally hold shares. It is unusual not to have at least some personal holdings of board members, so our data could be in error. A good next step would be to take a look at this free summary of insider buying and selling.

General public property

The general public, generally individual investors, holds 49% of the capital of Keymed Biosciences. Although this group may not necessarily make the decisions, they can certainly have a real influence on the way the business is run.

Private equity ownership

With a 9.3% stake, private equity firms are able to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private capital sticking around for the long haul, but generally they have a shorter investment horizon and, as the name suggests, don’t invest heavily in public companies. After a while, they may look to sell and redeploy capital elsewhere.

Private Company Ownership

Our data indicates that private companies hold 28% of the shares of society. Private companies can be related parties. Sometimes insiders have an interest in a public company through an equity stake in a private company, rather than in their own capacity as individuals. Although it is difficult to draw general conclusions, it should be noted that this is an area for further research.

Next steps:

While it is worth considering the different groups that own a business, there are other, even more important factors. To do this, you need to find out about the 2 warning signs we identified some with Keymed Biosciences (including 1 which is potentially serious) .

But finally it’s the future, not the past, which will determine the performance of the owners of this company. Therefore, we think it’s advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: The figures in this article are calculated using trailing twelve month data, which refers to the 12 month period ending on the last day of the month the financial statements are dated. This may not be consistent with the annual report figures for the full year.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Valuation is complex, but we help make it simple.

Find out if Keymed Biosciences is potentially overvalued or undervalued by viewing our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.

See the free analysis

Comments are closed.